Australia’s trusted immunisation experts
21 September 2023 | NewsMultiple vaccinations for children – new NCIRS resourceRead the full article
為了做出最適合您的決定,您可以將COVID-19所帶來的風險與接種疫苗所帶來的風險進行比較。
本頁所載表格内分別列出了兩者的風險,方便您進行比較。表格使用方法如下:
1.選擇您想進一步了解的疫苗。您的醫生可能會根據您的年齡或您所在地區的疫苗供應情況,推薦一款特定的疫苗。
2.選擇以人口百分比(%)或人口數量(例如,「每千人」或「每百萬人」)的方式,查看風險。
3.比較病毒的風險與疫苗的風險。點擊展開圖表,詳細查看特定症狀的風險。
Comirnaty是一種由Pfizer和BioNTech生產的疫苗。亦稱作BNT162b2或「Pfizer疫苗」。
它是一種mRNA疫苗,表示即它是使用來自病毒一部份的遺傳密碼來訓練您的免疫系統。該遺傳密碼會被身體迅速分解並清除。您不會因接種Comirnaty(Pfizer)疫苗而感染COVID-19。
COVID-19病毒持續產生微小的基因改變,稱為變異株。該疫苗對於一些變異株比另一些變異株更加有效。您仍有可能感染COVID-19。但如果您已接種最新一劑疫苗,您的病情會輕微很多。2-4
您將接種兩劑Pfizer疫苗,之間相隔三至六個星期。4建議您在接種完第二劑疫苗後的三個月接種加強劑。
下面表格對比了COVID-19的風險與Pfizer疫苗的風險。5-16
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. New England Journal of Medicine. 2021;385(7):585-94. Australian Technical Advisory Group on Immunisation (ATAGI). Clinical guidance on use of COVID-19 vaccine in Australia in 2021 (v7.0). Medicines and Healthcare Products Regulatory Agency. (2021). Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca. Available from: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca ATAGI reinforce recommendations on use of COVID-19 vaccines following review of vaccine safety data and benefits (2021). Available from: https://www.health.gov.au/news/atagi-reinforce-recommendations-on-use-of-covid-19-vaccines-following-review-of-vaccine-safety-data-and-benefits Pormohammad, A, Ghorbani, S, Khatami, A, et al. Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis. Rev Med Virol. 2020; 30:e2112. https://doi-org.ezproxy.lib.uts.edu.au/10.1002/rmv.2112 Australian Government Department of Health. 2021. Health Coronavirus Case Numbers and Statistics. https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics National Centre for Immunisation Research and Surveillance. AusVaxSafety. 2021. https://www.ausvaxsafety.org.au/ accessed September 2021 Therapeutic Goods Administration. 2021. COVID-19 vaccine safety report. https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-29-07-2021#section-694 Therapeutic Goods Administration. 2021. Consumer medicine information. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-01194-1&d=202103191016933&d=20210805172310101 Australian Government Department of Health. 2021. ATAGI update. https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-7-july-2021 Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. MedRxiv. 2021 Jan 1. https://osf.io/a9jdq/ Liu B, Jayasundara D, Pye V, Dobbins T, Dore GJ, Matthews G, Kaldor J, Spokes P. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. The Lancet Regional Health-Western Pacific. 2021 Jul 1;12:100193. https://www.sciencedirect.com/science/article/pii/S2666606521001024 Raveendran, A., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: An overview. Diabetes & Metabolic Syndrome Clinical Research & Reviews, 15(3):869–875. https://doi.org/10.1016/j.dsx.2021.04.007 Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, Yehia EG, Fineman S, Geller M, Gonzalez-Estrada A, Greenberger PA, Leung AS. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal. 2021 Feb 3:100517. https://www.worldallergyorganizationjournal.org/article/S1939-4551(21)00011-9/fulltext Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Academic Radiology. 2021 May 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088218/ Australian Government Department of Health. COVID-19 Australia: Epidemiology Report 53. Reporting period ending 24 October 2021.
Vaxzevria是一款由牛津大學和AstraZeneca所開發的疫苗。亦稱作「AstraZeneca疫苗」。 Vaxzevra(AstraZeneca)使用來自該病毒一部份的遺傳密碼來訓練您的免疫系統識別和抵抗COVID-19。這種疫苗與mRNA疫苗不同,因為該遺傳密碼是以修改過的或「滅活的」病毒(無害的普通感冒病毒)為載體,因此不會導致感染。您不會因接種Vaxzevra (AstraZeneca)疫苗而感染COVID-19。
COVID-19病毒持續產生微小的基因改變,稱為變異株。該疫苗對於一些變異株比另一些變異株更加有效。您仍有可能感染COVID-19。但如果您已接種最新一劑疫苗,您的病情會輕微很多。2-3
您將接種兩劑AstraZeneca疫苗,之間相隔四至十二個星期。2建議您在接種完第二劑疫苗後的三個月接種加強劑。
下面表格對比了COVID-19的風險與AstraZeneca疫苗的風險。2-15
由Moderna所開發的疫苗稱作「Spikevax」或「Moderna疫苗」。
它是一種mRNA疫苗,表示即它是使用來自病毒一部份的遺傳密碼來訓練您的免疫系統。該遺傳密碼會被身體迅速分解並清除。您不會因接種Spikevax(Moderna)疫苗而感染COVID-19。
COVID-19病毒持續產生微小的基因改變,稱為變異株。該疫苗對於一些變異株比另一些變異株更加有效。您仍有可能感染COVID-19。但如果您已接種最新一劑疫苗,您的病情會輕微很多。1
您將接種兩劑Moderna疫苗,之間相隔四至六個星期。1如果您年滿16歲,建議您在接種完第二劑疫苗後的六個月接種加強劑。
下面表格對比了COVID-19的風險與Moderna疫苗的風險。1-13